Special Issue

Strategies for the Next Generation of Antibody-Drug Conjugates: Utilizing Tumor Immunology and Microenvironmental Factors in ADC Design

Message from the Guest Editors

We are pleased to invite you to submit a paper to a Special Issue of Pharmaceutics entitled "Strategies for the Next Generation of Antibody–Drug Conjugates: Utilizing Tumor Immunology and Microenvironmental Factors in ADC Design".

This Special Issue aims to deliver a full inventory of the various formats of novel ADC designs, and explore their interaction with the tumor microenvironment (e.g., probody–drug conjugates), as well as their potential to improve their therapeutic efficacy via immunestimulating modifications (e.g., ISACs).

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: design, synthesis and evaluation of ADCs, with a special focus on their linkers and payloads as responsive elements for the tumor microenvironment, and immune stimulation design approaches. Due to the increasing diversity of ADC formats, articles encompassing a comparative analysis of traditional and developmental platforms are highly welcome.

I look forward to receiving your contribution.

Guest Editors

Dr. Zoltan Szekely

- 1. Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA
- 2. Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA

Prof. Dr. Stephen K. Burley

1. Rutgers Cancer Institute of New Jersey, Rutgers, The State University



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/205413

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

